Alternating treatment with the WEE1 inhibitor adavosertib and the PARP inhibitor olaparib helps control the growth of cancers with DNA repair defects with less toxicity than concurrent drug administration, according to data from a phase Ib trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

You do not currently have access to this content.